Keywords belzutifan HIF-2α biomarker pheochromocytoma paraganglioma Belzutifan for advanced pheochromocytoma/paraganglioma: A milestone for rare cancers Completion of the LITESPARK-015 trial (NCT04924075i) and the U.S. Food and Drug Administration (FDA) approval of belzutifan represent a landmark for patients with advanced pheochromocytoma/paraganglioma (PPGL)ii and, more broadly, for the rare cancer community.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile